Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incr...

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven signifi...

Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has ...

Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depressi...

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and Ch...

Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings re...